Israel’s Oramed (see here previously) has completed enrollment of patients for the Phase 3 trial of its oral insulin for the treatment of type 2 diabetes. Topline results of the trial are expected early 2023.

https://www.prnewswire.com/news-releases/oramed-completes-patient-enrollment-in-pivotal-phase-3-oral-insulin-study-ora-d-013-1-301538222.html